GleamWall
中文EN

FTH Faeth Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829802 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-775.6%
TTM EPS YoY-17.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-229.6%
ROA-204.7%
ROIC (approx.)-214.2%
Asset turnover—

Leverage & solvency

Liabilities / assets6.2%
Debt / equity0.00x
Current ratio16.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-162.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
SG&A expense$11.33M$13.04M
Operating income-$22.29M-$32.61M
Interest expense$32,000$90,000
Pretax income-$21.09M-$30.16M
Income tax$0$0
Net income-$21.09M-$30.16M
EBITDA-$22.17M-$32.06M
EPS (basic)-16.72-24.01
EPS (diluted)-16.72-24.01
Weighted avg. shares (diluted)1.26M1.26M
Balance sheet
Cash & equivalents$8.67M$9.99M
Short-term investments$12.52M$31.34M
Current assets$21.51M$41.93M
PP&E, net$82,000$417,000
Total assets$22.90M$45.36M
Current liabilities$4.25M$5.45M
Total liabilities$4.31M$6.97M
Shareholders' equity$18.59M$38.39M
Shares outstanding1.26M1.26M
Cash flow statement
Operating cash flow-$20.45M-$24.67M
Capital expenditure$16,000$146,000
Free cash flow-$20.47M-$24.82M
Investing cash flow$19.77M$22.44M
Financing cash flow-$645,000-$787,000
Depreciation & amortization$122,000$551,000
Stock-based compensation$1.27M$3.13M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.